Kathy D. Miller, MD, celebrates the release of data at this year's San Antonio Breast Cancer Symposium (SABCS), which witnessed great strides in the treatment of hormone receptor-positive, HER2-negative breast cancer.
Beginning with the updates on studies involving two oral selective estrogen receptor downregulators (SERDs), Dr Miller eagerly anticipates the introduction of these drugs to the clinical setting. AKT inhibitors in combination with hormone therapy was another site of therapeutic advance, with the agent capivasertib demonstrating significantly less toxicity than other agents targeting the PI3 kinase-AKT pathway. A positive report on adjuvant abemaciclib follows, and finally, good news regarding the POSITIVE trial, which addresses the issue of suspension of endocrine therapy during pregnancy.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: A Big Year at the San Antonio Breast Cancer Symposium 2022 - Medscape - Jan 04, 2023.
Comments